Feb 18, 2026 07:51AM
Jan 28, 2026 06:41AM
Dec 3, 2025 06:06AM
Nov 24, 2025 07:33AM
Sep 16, 2025 05:23AM
May 20, 2025 07:01AM
May 7, 2025 04:31PM Viridian Therapeutics (VRDN) Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease
Jan 7, 2025 08:29AM
Dec 16, 2024 07:05AM
Nov 25, 2024 05:32AM
Sep 10, 2024 01:08PM
Sep 10, 2024 11:41AM
Sep 10, 2024 07:02AM
Aug 14, 2024 03:58PM Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jul 16, 2024 10:52AM
Jun 6, 2024 05:11AM
Jan 8, 2024 08:13AM
Dec 18, 2023 07:02AM
Oct 30, 2023 08:31AM
Jul 10, 2023 04:01PM
Jun 14, 2023 05:55AM BTIG Starts Viridian Therapeutic (VRDN) at Buy
Mar 29, 2023 04:08PM
Dec 1, 2022 06:29AM
Nov 30, 2022 10:39AM
Nov 30, 2022 09:36AM
Nov 30, 2022 09:34AM
Nov 14, 2022 06:59AM
Oct 24, 2022 05:52AM Viridian Therapeutics (VRDN) Reports Positive Data from Ongoing VRDN-001 Phase 1/2 Trial
Aug 16, 2022 06:17AM
Aug 15, 2022 06:59AM
May 13, 2022 05:59AM
Jan 31, 2022 07:01AM
Jan 4, 2022 07:05AM
Nov 15, 2021 07:01AM
Oct 14, 2021 08:03AM Viridian Therapeutics (VRDN) Submits IND for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to FDA

14,665 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All